Drug safety of oral iron chelator deferiprone in children: = Arzneimittelsicherheit des oralen Eisenchelators Deferipron bei Kindern
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Abschlussarbeit Buch |
| Sprache: | English |
| Veröffentlicht: |
Erlangen ; Nürnberg
[2017]
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | xi, 193 Seiten Illustrationen, Diagramme 30 cm |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV044549376 | ||
| 003 | DE-604 | ||
| 005 | 20181109 | ||
| 007 | t | ||
| 008 | 171020s2017 gw a||| m||| 00||| eng d | ||
| 016 | 7 | |a 1141938766 |2 DE-101 | |
| 035 | |a (OCoLC)1017028615 | ||
| 035 | |a (DE-599)DNB1141938766 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE | ||
| 049 | |a DE-29T |a DE-29 |a DE-355 | ||
| 100 | 1 | |a Botzenhardt, Sebastian |d 1985- |e Verfasser |0 (DE-588)1141938375 |4 aut | |
| 245 | 1 | 0 | |a Drug safety of oral iron chelator deferiprone in children |b = Arzneimittelsicherheit des oralen Eisenchelators Deferipron bei Kindern |c vorgelegt von Sebastian Botzenhardt |
| 246 | 1 | 3 | |a Arzneimittelsicherheit des oralen Eisenchelators Deferipron bei Kindern |
| 246 | 1 | 1 | |a Arzneimittelsicherheit des oralen Eisenchelators Deferipron bei Kindern |
| 264 | 1 | |a Erlangen ; Nürnberg |c [2017] | |
| 300 | |a xi, 193 Seiten |b Illustrationen, Diagramme |c 30 cm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 502 | |b Dissertation |c Friedrich-Alexander-Universität Erlangen-Nürnberg |d 2017 | ||
| 650 | 0 | 7 | |a Eisenkomplexe |0 (DE-588)4222910-8 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Kind |0 (DE-588)4030550-8 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Komplexbildner |0 (DE-588)4164886-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Thalassämie |0 (DE-588)4184972-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Metallchelate |0 (DE-588)4169575-6 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelsicherheit |0 (DE-588)4143182-0 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4113937-9 |a Hochschulschrift |2 gnd-content | |
| 689 | 0 | 0 | |a Kind |0 (DE-588)4030550-8 |D s |
| 689 | 0 | 1 | |a Thalassämie |0 (DE-588)4184972-3 |D s |
| 689 | 0 | 2 | |a Arzneimittelsicherheit |0 (DE-588)4143182-0 |D s |
| 689 | 0 | 3 | |a Komplexbildner |0 (DE-588)4164886-9 |D s |
| 689 | 0 | 4 | |a Eisenkomplexe |0 (DE-588)4222910-8 |D s |
| 689 | 0 | 5 | |a Metallchelate |0 (DE-588)4169575-6 |D s |
| 689 | 0 | |5 DE-604 | |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029948267&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029948267 | ||
Datensatz im Suchindex
| _version_ | 1804177912453136384 |
|---|---|
| adam_text | CONTENTS
DISCLOSURE.......................................................................................................................
V
ABSTRACT...................................................................................................................................................VI
ZUSAMMENFASSUNG..............................................................................................................................
IX
1 GENERAL
INTRODUCTION.............................................................................................................1
1.1 BACKGROUND AND
RATIONALE...........................................................................................................
2
1.2 DRUG USE IN
PAEDIATRICS.................................................................................................................5
1.2.1 CLINICAL
PHARMACOLOGY...............................................................................................................
5
1.2.2 OFF-LABEL
USE.................................................................................................................................7
1.2.3 EU REGULATORY
INITIATIVES............................................................................................................
8
1.2.4 ADVERSE DRUG
REACTIONS...............................................................................................................
9
1.2.5 PHARMACOVIGILANCE AND PHARMACOEPIDEMIOLOGY
....................................................................
11
1.3 HEREDITARY HAEMOGLOBINOPATHIES
.............................................................................................
13
1.3.1
CLASSIFICATION............................................................................................................................
13
1.3.2 SICKLE CELL
DISEASE.......................................................................................................................14
1.3.3
THALASSAEMIA............................................................................................................................
15
1.4
SS-THALASSAEMIA............................................................................................................................
16
1.4.1
PATHOPHYSIOLOGY........................................................................................................................16
1.4.2
EPIDEMIOLOGY............................................................................................................................
17
1.4.3 CLINICAL MANIFESTATIONS AND MANAGEMENT
.............................................................................
19
1.5 TRANSFUSIONAL IRON
OVERLOAD......................................................................................................22
1.5.1 IRON
METABOLISM......................................................................................................................
22
1.5.2
PATHOPHYSIOLOGY.......................................................................................................................
23
1.5.3
MONITORING...............................................................................................................................
23
1.5.4
COMPLICATIONS..........................................................................................................................23
1.5.5 T
REATMENT................................................................................................................................
24
1.6
DEFERIPRONE................................................................................................................................
26
1.6.1 PHARMACEUTICAL
CHEMISTRY.......................................................................................................
26
1.6.2
PHARMACODYNAMICS.................................................................................................................
27
1.6.3
PHARMACOKINETICS.....................................................................................................................28
1.6.4
PHARMACOGENETICS....................................................................................................................29
1.6.5 DRUG
FORMULATIONS..................................................................................................................
29
1.6.6 CLINICAL
EFFICACY........................................................................................................................
30
1.6.7 CLINICAL
SAFETY...........................................................................................................................
31
1.6.8 COMPLIANCE AND QUALITY OF
LIFE.........................................................................................
35
1.6.9 MARKETING AND
PHARMACOECONOMICS......................................................................................
35
2 PART I: SAFETY OF IRON CHELATORS IN YOUNG PATIENTS WITH
HAEMOGLOBINOPATHIES...........................................................................................................
37
2.1
INTRODUCTION................................................................................................................................
38
2.2
METHODS........................................................................................................................................39
2.2.1 DATA SOURCES AND SEARCH
STRATEGY............................................................................................
39
2.2.2 STUDY
SELECTION..........................................................................................................................39
2.2.3 DATA
COLLECTION..........................................................................................................................40
2.2.4 QUALITY
ASSESSMENT...................................................................................................................
40
2.2.5 DATA
SYNTHESIS...........................................................................................................................40
2.3
RESULTS...........................................................................................................................................41
2.3.1 LITERATURE SEARCH
RESULTS..........................................................................................................
41
2.3.2 META-ANALYSIS OF REPORTED AE INCIDENCES
..............................................................................
47
2.3.3 QUALITY ASSESSMENT
RESULTS................................................ 47
2.3.4 DEFEROXAMINE (DFO)
MONOTHERAPY.......................................................................................
50
2.3.5 DEFERIPRONE (DFP)
MONOTHERAPY...........................................................................................
50
2.3.6 DEFERASIROX (DFX)
MONOTHERAPY............................................................................................
51
2.3.7 SEQUENTIAL DEFERIPRONE AND DEFEROXAMINE COMBINATION (SEQ DFP+DFO)
........................
52
2.3.8 SEQUENTIAL DEFERASIROX AND DEFEROXAMINE COMBINATION (SEQ
DFX+DFO).........................52
2.3.9 SIMULTANEOUS DEFERIPRONE AND DEFEROXAMINE COMBINATION (SIM
DFP+DFO)
....................
52
2.3.10 SIMULTANEOUS DEFERIPRONE AND DEFERASIROX COMBINATION (SIM
DFP+DFX)
........................
53
2.3.11 DISCONTINUATION RATE DUE TO ADVERSE
EVENTS............................................................................53
2.4
DISCUSSION....................................................................................................................................
54
2.4.1 STRENGTHS AND
LIMITATIONS.........................................................................................................
54
2.4.2 ADVERSE EFFECTS REPORTING
QUALITY............................................................................................54
2.4.3 GENERAL
CONSIDERATIONS............................................................................................................
55
2.4.4 SAFETY PROFILE OF DEFEROXAMINE
(DFO)....................................................................................
55
2.4.5 SAFETY PROFILE OF DEFERIPRONE
(DFP)........................................................................................56
2.4.6 SAFETY PROFILE OF DEFERASIROX
(DFX).........................................................................................
57
2.4.7 SAFETY PROFILE OF COMBINED IRON CHELATION REGIMENS
.............................................................
58
3 PART II: SAFETY OF DEFERIPRONE THERAPY IN CHINESE CHILDREN WITH
THALASSAEMIA...............................................................................................................................
59
3.1
INTRODUCTION................................................................................................................................60
3.2
METHODS.......................................................................................................................................
61
3.2.1 STUDY
DESIGN.............................................................................................................................
61
3.2.2 DATA
SOURCE...............................................................................................................................
61
3.2.3 DATA
COLLECTION.........................................................................................................................
61
3.2.4 STUDY POPULATION AND OBSERVATION PERIOD
.............................................................................
62
3.2.5 ADVERSE DRUG REACTION
IDENTIFICATION......................................................................................
62
3.2.6 STATISTICAL
ANALYSIS.....................................................................................................................63
3.3
RESULTS..........................................................................................................................................
64
3.3.1 PATIENT
CHARACTERISTICS..............................................................................................................
64
3.3.2 IDENTIFIED ADVERSE DRUG
REACTIONS............................................................................................65
3.3.3 NEUTROPENIA AND
AGRANULOCYTOSIS...........................................................................................66
3.3.4 OTHER IDENTIFIED
ADRS.............................................................................................................
67
3.3.5 TREATMENT
DISCONTINUATIONS....................................................................................................69
3.4
DISCUSSION....................................................................................................................................70
3.4.1 STRENGTHS AND
LIMITATIONS........................................................................................................70
3.4.2 NEUTROPENIA AND
AGRANULOCYTOSIS...........................................................................................70
3.4.3 OTHER ADVERSE DRUG
REACTIONS...................................................................................................71
3.4.4 TREATMENT
DURATION..................................................................................................................72
4 PART ILLS LONG-TERM SAFETY OF DEFERIPRONE IN PAEDIATRIC PATIENTS WITH
SS-THALASSAEMIA
MAJOR............................................................................................................
73
4.1
INTRODUCTION................................................................................................................................74
4.2
METHODS.......................................................................................................................................75
4.2.1 STUDY DESIGN AND PATIENT RECRUITMENT
..........................................
75
4.2.2 DATA
COLLECTION.........................................................................................................................
76
4.2.3
DEFINITIONS................................................................................................................................77
4.2.4 ADVERSE DRUG REACTION IDENTIFICATION
PROCESS.........................................................................79
4.2.5 SAMPLE
SIZE...............................................................................................................................80
4.2.6 STATISTICAL METHODS AND DATA MANAGEMENT
............................................................................
80
4.3
RESULTS..........................................................................................................................................82
4.3.1 STUDY
POPULATION.....................................................................................................................82
4.3.2 CHELATION
CHARACTERISTICS.........................................................................................................84
4.3.3 LABORATORY
PARAMETERS............................................................................................................86
4.3.4 IDENTIFIED ADVERSE DRUG REACTIONS TO
DEFERIPRONE...................................................................88
4.3.5 END OF FOLLOW-UP AND PERMANENT DFP
WITHDRAWAL...............................................................95
4.3.6 POTENTIAL RISK FACTORS FOR ADR OCCURRENCE AND DFP DISCONTINUATION
.................................
98
4.4
DISCUSSION...................................................................................................................................
99
4.4.1 STRENGTHS AND
LIMITATIONS.......................................................................................................
99
4.4.2 OBSTACLES DURING STUDY
IMPLEMENTATION..............................................................................
100
4.4.3 LABORATORY PARAMETERS AND CLINICAL
EFFECTIVENESS................................................................101
4.4.4 NEUTROPENIA AND
AGRANULOCYTOSIS.........................................................................................101
4.4.5
ARTHROPATHY...........................................................................................................................102
4.4.6 INCREASED
TRANSAMINASES........................................................................................................103
4.4.7 GASTROINTESTINAL
DISORDERS......................................................................................................103
4.4.8 ADR-RELATED DRUG
WITHDRAWALS.............................................................................................
103
5 GENERAL
CONCLUSION..............................................................................................................
105
5.1 RESULTS OF THIS WORK IN THE CONTEXT OF EXISTING
DATA.............................................................106
5.1.1 OVERALL
FINDINGS......................................................................................................................
106
5.1.2 PERMANENT THERAPY
DISCONTINUATIONS....................................................................................107
5.1.3
AGRANULOCYTOSIS......................................................................................................................
107
5.1.4 N
EUTROPENIA............................................................................................................................
108
5.1.5
ARTHROPATHY...........................................................................................................................
109
5.1.6 INCREASED
TRANSAMINASES.........................................................................................................109
5.1.7 GASTROINTESTINAL
DISORDERS......................................................................................................109
5.1.8
THROMBOCYTOPENIA................................................................................................................
109
5.1.9 OTHER ADVERSE DRUG
REACTIONS.................................................................................................
110
5.2 RECOMMENDATIONS ON DFP SAFETY IN CHILDREN AND ADOLESCENTS
........................................
I L L
5.3
PERSPECTIVE.................................................................................................................................
113
ACKNOWLEDGEMENTS..............................................................................................................
114
REFERENCES............................................................................................................................................
116
ABBREVIATIONS.....................................................................................................................................132
LIST OF
FIGURES.....................................................................................................................................134
LIST OF
TABLES.......................................................................................................................................135
CURRICULUM VITAE
.........................
136
LIST OF PUBLICATIONS AND
PRESENTATIONS...........................................................................138
APPENDIX.................................................................................................................................................
140
APPENDIX 1: SYSTEMATIC LITERATURE SEARCH
STRATEGIES..........................................................................141
APPENDIX 2: FOREST PLOTS OF POOLED ADVERSE EVENT INCIDENCES FROM
PUBLISHED LITERATURE
..........
146
APPENDIX 3: IDENTIFIED CASES OF SERIOUS ADRS TO DEFERIPRONE IN CHINESE
CHILDREN
.....................
159
APPENDIX 4: USED CAUSALITY AND SEVERITY ASSESSMENT ALGORITHMS
....................................................
162
APPENDIX 5: DEEP-3 CASE REPORT FORM
(CRF)...................................................................................
164
APPENDIX 6: DEEP-3 ELECTRONIC CASE REPORT FORM (ECRF)
EXCERPT.................................................. 192
|
| any_adam_object | 1 |
| author | Botzenhardt, Sebastian 1985- |
| author_GND | (DE-588)1141938375 |
| author_facet | Botzenhardt, Sebastian 1985- |
| author_role | aut |
| author_sort | Botzenhardt, Sebastian 1985- |
| author_variant | s b sb |
| building | Verbundindex |
| bvnumber | BV044549376 |
| ctrlnum | (OCoLC)1017028615 (DE-599)DNB1141938766 |
| format | Thesis Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02204nam a2200481 c 4500</leader><controlfield tag="001">BV044549376</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20181109 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">171020s2017 gw a||| m||| 00||| eng d</controlfield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1141938766</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1017028615</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1141938766</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29T</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-355</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Botzenhardt, Sebastian</subfield><subfield code="d">1985-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1141938375</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Drug safety of oral iron chelator deferiprone in children</subfield><subfield code="b">= Arzneimittelsicherheit des oralen Eisenchelators Deferipron bei Kindern</subfield><subfield code="c">vorgelegt von Sebastian Botzenhardt</subfield></datafield><datafield tag="246" ind1="1" ind2="3"><subfield code="a">Arzneimittelsicherheit des oralen Eisenchelators Deferipron bei Kindern</subfield></datafield><datafield tag="246" ind1="1" ind2="1"><subfield code="a">Arzneimittelsicherheit des oralen Eisenchelators Deferipron bei Kindern</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Erlangen ; Nürnberg</subfield><subfield code="c">[2017]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">xi, 193 Seiten</subfield><subfield code="b">Illustrationen, Diagramme</subfield><subfield code="c">30 cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="502" ind1=" " ind2=" "><subfield code="b">Dissertation</subfield><subfield code="c">Friedrich-Alexander-Universität Erlangen-Nürnberg</subfield><subfield code="d">2017</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Eisenkomplexe</subfield><subfield code="0">(DE-588)4222910-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Kind</subfield><subfield code="0">(DE-588)4030550-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Komplexbildner</subfield><subfield code="0">(DE-588)4164886-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Thalassämie</subfield><subfield code="0">(DE-588)4184972-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Metallchelate</subfield><subfield code="0">(DE-588)4169575-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelsicherheit</subfield><subfield code="0">(DE-588)4143182-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4113937-9</subfield><subfield code="a">Hochschulschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Kind</subfield><subfield code="0">(DE-588)4030550-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Thalassämie</subfield><subfield code="0">(DE-588)4184972-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Arzneimittelsicherheit</subfield><subfield code="0">(DE-588)4143182-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Komplexbildner</subfield><subfield code="0">(DE-588)4164886-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="4"><subfield code="a">Eisenkomplexe</subfield><subfield code="0">(DE-588)4222910-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="5"><subfield code="a">Metallchelate</subfield><subfield code="0">(DE-588)4169575-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029948267&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029948267</subfield></datafield></record></collection> |
| genre | (DE-588)4113937-9 Hochschulschrift gnd-content |
| genre_facet | Hochschulschrift |
| id | DE-604.BV044549376 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T07:55:37Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029948267 |
| oclc_num | 1017028615 |
| open_access_boolean | |
| owner | DE-29T DE-29 DE-355 DE-BY-UBR |
| owner_facet | DE-29T DE-29 DE-355 DE-BY-UBR |
| physical | xi, 193 Seiten Illustrationen, Diagramme 30 cm |
| publishDate | 2017 |
| publishDateSearch | 2017 |
| publishDateSort | 2017 |
| record_format | marc |
| spelling | Botzenhardt, Sebastian 1985- Verfasser (DE-588)1141938375 aut Drug safety of oral iron chelator deferiprone in children = Arzneimittelsicherheit des oralen Eisenchelators Deferipron bei Kindern vorgelegt von Sebastian Botzenhardt Arzneimittelsicherheit des oralen Eisenchelators Deferipron bei Kindern Erlangen ; Nürnberg [2017] xi, 193 Seiten Illustrationen, Diagramme 30 cm txt rdacontent n rdamedia nc rdacarrier Dissertation Friedrich-Alexander-Universität Erlangen-Nürnberg 2017 Eisenkomplexe (DE-588)4222910-8 gnd rswk-swf Kind (DE-588)4030550-8 gnd rswk-swf Komplexbildner (DE-588)4164886-9 gnd rswk-swf Thalassämie (DE-588)4184972-3 gnd rswk-swf Metallchelate (DE-588)4169575-6 gnd rswk-swf Arzneimittelsicherheit (DE-588)4143182-0 gnd rswk-swf (DE-588)4113937-9 Hochschulschrift gnd-content Kind (DE-588)4030550-8 s Thalassämie (DE-588)4184972-3 s Arzneimittelsicherheit (DE-588)4143182-0 s Komplexbildner (DE-588)4164886-9 s Eisenkomplexe (DE-588)4222910-8 s Metallchelate (DE-588)4169575-6 s DE-604 DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029948267&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Botzenhardt, Sebastian 1985- Drug safety of oral iron chelator deferiprone in children = Arzneimittelsicherheit des oralen Eisenchelators Deferipron bei Kindern Eisenkomplexe (DE-588)4222910-8 gnd Kind (DE-588)4030550-8 gnd Komplexbildner (DE-588)4164886-9 gnd Thalassämie (DE-588)4184972-3 gnd Metallchelate (DE-588)4169575-6 gnd Arzneimittelsicherheit (DE-588)4143182-0 gnd |
| subject_GND | (DE-588)4222910-8 (DE-588)4030550-8 (DE-588)4164886-9 (DE-588)4184972-3 (DE-588)4169575-6 (DE-588)4143182-0 (DE-588)4113937-9 |
| title | Drug safety of oral iron chelator deferiprone in children = Arzneimittelsicherheit des oralen Eisenchelators Deferipron bei Kindern |
| title_alt | Arzneimittelsicherheit des oralen Eisenchelators Deferipron bei Kindern |
| title_auth | Drug safety of oral iron chelator deferiprone in children = Arzneimittelsicherheit des oralen Eisenchelators Deferipron bei Kindern |
| title_exact_search | Drug safety of oral iron chelator deferiprone in children = Arzneimittelsicherheit des oralen Eisenchelators Deferipron bei Kindern |
| title_full | Drug safety of oral iron chelator deferiprone in children = Arzneimittelsicherheit des oralen Eisenchelators Deferipron bei Kindern vorgelegt von Sebastian Botzenhardt |
| title_fullStr | Drug safety of oral iron chelator deferiprone in children = Arzneimittelsicherheit des oralen Eisenchelators Deferipron bei Kindern vorgelegt von Sebastian Botzenhardt |
| title_full_unstemmed | Drug safety of oral iron chelator deferiprone in children = Arzneimittelsicherheit des oralen Eisenchelators Deferipron bei Kindern vorgelegt von Sebastian Botzenhardt |
| title_short | Drug safety of oral iron chelator deferiprone in children |
| title_sort | drug safety of oral iron chelator deferiprone in children arzneimittelsicherheit des oralen eisenchelators deferipron bei kindern |
| title_sub | = Arzneimittelsicherheit des oralen Eisenchelators Deferipron bei Kindern |
| topic | Eisenkomplexe (DE-588)4222910-8 gnd Kind (DE-588)4030550-8 gnd Komplexbildner (DE-588)4164886-9 gnd Thalassämie (DE-588)4184972-3 gnd Metallchelate (DE-588)4169575-6 gnd Arzneimittelsicherheit (DE-588)4143182-0 gnd |
| topic_facet | Eisenkomplexe Kind Komplexbildner Thalassämie Metallchelate Arzneimittelsicherheit Hochschulschrift |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029948267&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT botzenhardtsebastian drugsafetyoforalironchelatordeferiproneinchildrenarzneimittelsicherheitdesoraleneisenchelatorsdeferipronbeikindern AT botzenhardtsebastian arzneimittelsicherheitdesoraleneisenchelatorsdeferipronbeikindern |